Opinion
Video
Evolving HER2+ Breast Cancer Care: Neo-Adjuvant Strategies and Treatment Goals
Experts explore neoadjuvant HER2+ breast cancer care; delve into treatment goals, predictors, and personalized approaches; and uncover insights on chemotherapy, trastuzumab, and postoperative considerations.
This is a video synopsis/summary of a Peer Exchange involving Joyce O’Shaughnessy, MD; Priyanka Sharma, MD; Claudine Isaacs, MD; Heather McArthur, MD; and Hope S. Rugo, MD, FASCO.
In this oncology discussion led by O’Shaughnessy, experts explore recent data updates shaping clinical practices for patients with HER2-positive breast cancer. The panel discusses the significance of neoadjuvant treatment, emphasizing goals such as achieving a pathologic complete response and tailoring strategies based on disease burden, hormone receptor status, and genomic predictors. Pertuzumab’s role is scrutinized, and the impact of a patient’s age on long-term prognosis is assessed. The dialogue offers insights into evolving management practices, incorporating recent trial data to refine HER2-positive breast cancer care. It serves as a valuable resource for health care professionals navigating the latest advancements and challenges in this field.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
